• Je něco špatně v tomto záznamu ?

Methylation status of selected genes in non-small cell lung carcinoma - current knowledge and future perspectives

A. Put, K. Smesny Trtkova, J. Skarda

. 2024 ; 71 (6) : 511-532. [pub] -

Jazyk angličtina Země Slovensko

Typ dokumentu časopisecké články, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc25010580

DNA methylation is recognized as an early event in cancer initiation and progression. This review aimed to compare the methylation status of promoter regions in selected genes across different histological subtypes of non-small cell lung cancer (NSCLC), including adenocarcinoma, squamous cell carcinoma, large cell carcinoma, and the rare but highly aggressive large-cell neuroendocrine carcinoma (LCNEC). A comprehensive literature search was conducted in the PubMed database until August 17, 2024, using standardized keywords to identify reports on promoter methylation in NSCLC. Seventy-five studies were reviewed, focusing on the promoter methylation of key genes, such as APC, BRCA1, CDH1, CDH13, DAPK1, DLEC1, FHIT, GSTP1, hMLH1, MGMT, CDKN2A, RARβ, RASSF1, RUNX3, and TIMP3. These studies explored diagnostic, prognostic, epidemiological, and therapeutic aspects across NSCLC subtypes. Additionally, mutational profiles of TP53, RB1, KEAP1, and STK11 and expression patterns of ASCL1, DLL3, and NOTCH were analyzed. The findings suggest that LCNEC may serve as a biological bridge between non-small cell and small-cell lung carcinoma. Our analysis highlights that the methylation status of selected genes could enhance diagnosis, prognosis, and personalized treatment strategies in patients with NSCLC, particularly those with LCNEC.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25010580
003      
CZ-PrNML
005      
20250429134747.0
007      
ta
008      
250415s2024 xo f 000 0|eng||
009      
AR
024    7_
$a 10.4149/neo_2024_240925N403 $2 doi
035    __
$a (PubMed)39832203
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xo
100    1_
$a Put, Adam $u Department of Clinical and Molecular Pathology and Medical Genetics, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic $u Department of Clinical and Molecular Pathology and Medical Genetics, Faculty Hospital Ostrava, Ostrava, Czech Republic
245    10
$a Methylation status of selected genes in non-small cell lung carcinoma - current knowledge and future perspectives / $c A. Put, K. Smesny Trtkova, J. Skarda
520    9_
$a DNA methylation is recognized as an early event in cancer initiation and progression. This review aimed to compare the methylation status of promoter regions in selected genes across different histological subtypes of non-small cell lung cancer (NSCLC), including adenocarcinoma, squamous cell carcinoma, large cell carcinoma, and the rare but highly aggressive large-cell neuroendocrine carcinoma (LCNEC). A comprehensive literature search was conducted in the PubMed database until August 17, 2024, using standardized keywords to identify reports on promoter methylation in NSCLC. Seventy-five studies were reviewed, focusing on the promoter methylation of key genes, such as APC, BRCA1, CDH1, CDH13, DAPK1, DLEC1, FHIT, GSTP1, hMLH1, MGMT, CDKN2A, RARβ, RASSF1, RUNX3, and TIMP3. These studies explored diagnostic, prognostic, epidemiological, and therapeutic aspects across NSCLC subtypes. Additionally, mutational profiles of TP53, RB1, KEAP1, and STK11 and expression patterns of ASCL1, DLL3, and NOTCH were analyzed. The findings suggest that LCNEC may serve as a biological bridge between non-small cell and small-cell lung carcinoma. Our analysis highlights that the methylation status of selected genes could enhance diagnosis, prognosis, and personalized treatment strategies in patients with NSCLC, particularly those with LCNEC.
650    _2
$a lidé $7 D006801
650    12
$a nemalobuněčný karcinom plic $x genetika $x patologie $7 D002289
650    12
$a metylace DNA $7 D019175
650    12
$a nádory plic $x genetika $x patologie $7 D008175
650    _2
$a promotorové oblasti (genetika) $x genetika $7 D011401
650    _2
$a prognóza $7 D011379
650    _2
$a nádorové biomarkery $x genetika $7 D014408
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Smesny Trtkova, Katerina $u Department of Clinical and Molecular Pathology and Medical Genetics, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic $u Department of Clinical and Molecular Pathology and Medical Genetics, Faculty Hospital Ostrava, Ostrava, Czech Republic $u Department of Clinical and Molecular Pathology, Faculty of Medicine, Palacky University Olomouc, Olomouc, Czech Republic
700    1_
$a Skarda, Jozef $u Department of Clinical and Molecular Pathology and Medical Genetics, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic $u Department of Clinical and Molecular Pathology and Medical Genetics, Faculty Hospital Ostrava, Ostrava, Czech Republic $u Department of Clinical and Molecular Pathology, Faculty of Medicine, Palacky University Olomouc, Olomouc, Czech Republic
773    0_
$w MED00003470 $t Neoplasma $x 0028-2685 $g Roč. 71, č. 6 (2024), s. 511-532
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39832203 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250415 $b ABA008
991    __
$a 20250429134743 $b ABA008
999    __
$a ok $b bmc $g 2311760 $s 1247661
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 71 $c 6 $d 511-532 $e - $i 0028-2685 $m Neoplasma $n Neoplasma $x MED00003470
LZP    __
$a Pubmed-20250415

Najít záznam

Citační ukazatele

Možnosti archivace